ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment
ANN ARBOR, MI – November 12, 2014
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced that the company has been awarded a $1.37 million Small Business Innovation Research (SBIR) Phase II contract from the National Eye Institute (NEI) to advance development of ONL101, the company’s lead therapeutic candidate. ONL101 is a first-in-class small molecule peptide initially being developed for the protection of photoreceptors in retinal detachment, a condition for which the product has been granted orphan disease designation. This grant will be used to support the remaining ONL101 preclinical development activities required for submission of an investigational new drug (IND) application.
ONL received this funding following the successful completion of a Phase I SBIR project which focused on demonstrating the feasibility of the company’s approach to blocking photoreceptor apoptosis in retinal detachment animal models. This NEI-funded research showed that ONL could deliver the target molecule intravitreally and achieve sufficient retinal concentrations to block apoptosis.
“Receipt of this second SBIR grant from the National Eye Institute provides further validation for our foundational photoreceptor protection technology, as well as our ONL101 product,” said John Freshley, chief executive officer of ONL Therapeutics. “This funding will allow for continued evaluation of ONL101’s ability to protect photoreceptors in cases of retinal detachment and, ultimately, preserve vision. Illustrating this mechanism of photoreceptor protection not only helps advance ONL101 as a treatment for retinal detachment but also provides rationale for the technology’s application to other important retinal diseases such as wet and dry age-related macular degeneration.”
In addition to the SBIR grant, ONL has also raised $1.0 million through a convertible bridge loan from a syndicate led by the Capital Community Angels of Lansing, Michigan. Additional investors included Biosciences Research & Commercialization Center (with funds from the Michigan Economic Development Corporation), ONL management and other unnamed investors. The bridge loan will convert to Series A Preferred shares concurrent with the closing of a Series A financing. Combined, the SBIR grant and bridge loan provide ONL with sufficient capital to complete IND-enabling studies for ONL101.
ONL101 is a first-in-class therapeutic that works by protecting photoreceptors against the programmed cell death (apoptosis) that occurs during the course of a broad range of retinal diseases and conditions. It is this death of photoreceptors that is the root cause of vision loss and the leading cause of blindness. Preclinical data to date for the product demonstrates its ability to protect photoreceptors against the apoptosis process triggered by retinal detachment. In in vivo retinal detachment models, up to 80 percent of the photoreceptor cells that would normally die without treatment were kept alive following administration of ONL101.
ONL is currently preparing for IND-enabling preclinical activities for ONL101 with the expectation of submitting an IND application in late 2015 to support the initiation of a Phase 1 clinical trial in retinal detachment. The company has already completed a pre-IND meeting with the United States Food and Drug Administration (FDA) and the agency has deemed the company’s clinical development plan for ONL101 as acceptable.
About ONL Therapeutics
ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions. By advancing a novel breakthrough technology designed to protect photoreceptors against programmed cell death (apoptosis), ONL is pioneering an entirely new approach to preserving sight. The company’s lead therapeutic candidate, ONL101, is a first-in-class small molecule peptide initially being developed for the protection of photoreceptors in retinal detachment, a condition for which the product has been granted orphan disease designation. ONL plans to submit an investigational new drug (IND) application for ONL101 in late 2015 to support the initiation of a Phase 1 clinical trial in retinal detachment. For more information about ONL Therapeutics, please visit www.onltherapeutics.com
ONL Therapeutics, Inc.
John Freshley, Chief Executive Officer
Vida Strategic Partners (On behalf of ONL)
Stephanie Diaz (investors)
Tim Brons (media)